Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study

Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study

SARS-CoV-2 vaccination campaigns on current endemic situation would benefit from vaccine alternatives with easy logistics and accessibility, sustained response and cross-reactivity against emerging variants. Herein, safety and immunogenicity of PHH-1V, adjuvanted recombinant RBD-based vaccine, as fo...

Full description

Saved in:
Bibliographic Details
Main Authors: María Jesús López, Maria Del Mar Vazquez, Melchor Alvarez-Mon, José Ramón Arribas, Eunate Arana-Arri, Patricia Muñoz, Jorge Navarro-Pérez, Rafael Ramos, José Molto, Susana Otero-Romero, Elena Aurrecoechea, Roc Pomarol, Laia Bernad, Ignasi Esteban, Raúl Pérez-Caballero, Montserrat Plana, Júlia G. Prado, Álex Soriano
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Protein vaccine
omicron subvariants
vaccine booster
SARS-CoV-2
COVID-19
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2025.2474775
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2025.2474775

Similar Items